(249/250)ObjectiveObservational data suggest hope is associated with the quality of life and survival of people with cancer. This trial examined the feasibility, acceptability, and preliminary outcomes of “Pathways,” a hope intervention for people in treatment for advanced lung cancer.MethodsBetween 2020 and 2022, we conducted a single‐arm trial of Pathways among participants who were 3–12 weeks into systemic treatment. Pathways consisted of two individual sessions delivered during infusions and three phone calls in which participants discussed their values, goals, and goal strategies with a nurse or occupational therapist. Participants completed standardized measures of hope and goal interference pre‐ and post‐intervention. Feasibility was defined as ≥60% of eligible patients enrolling, ≥70% of participants completing three or more sessions, ≥70% of participants completing post‐assessments, and mean acceptability ratings ≥7 out of 10 on intervention relevance, helpfulness, and convenience. Linear regression fixed effects models with covariates modeled pre–post changes in complete case analysis and multiple imputation models.ResultsFifty two participants enrolled: female (59.6%), non‐Hispanic White (84.6%), rural (75.0%), and with low educational attainment (51.9% high school degree or less). Except for enrollment (54%), feasibility and acceptability markers were surpassed (77% adherence, 77% retention, acceptability ratings ≥8/10). There was moderate improvement in hope and goal interference from pre‐to post‐intervention (d = 0.51, p < 0.05 for hope; d = −0.70, p < 0.005 for goal interference).ConclusionsStrong feasibility, acceptability, and patient‐reported outcome data suggest Pathways is a promising intervention to increase hope and reduce cancer‐related goal interference during advanced lung cancer treatment.

中文翻译：

---

“路径”：为接受晚期肺癌治疗的患者增强希望的干预措施

(249/250)客观观察数据表明希望与癌症患者的生活质量和生存率有关。该试验检验了“Pathways”的可行性、可接受性和初步结果，这是对晚期肺癌治疗患者的希望干预措施。方法在 2020 年至 2022 年期间，我们在 3-12 周的参与者中进行了 Pathways 的单臂试验进入系统治疗。途径包括在输液期间进行的两次单独会议和三个电话，参与者在电话中与护士或职业治疗师讨论他们的价值观、目标和目标策略。参与者在干预前后完成了希望和目标干扰的标准化测量。可行性定义为≥60%的合格患者入组，≥70%的参与者完成三个或更多疗程，≥70%的参与者完成后评估，并且干预相关性、帮助性和便利性的平均可接受性评级≥7（满分10） 。线性回归固定效应模型，其中协变量在完整病例分析和多重插补模型中建模前后变化。 结果 52 名参与者入组：女性 (59.6%)、非西班牙裔白人 (84.6%)、农村 (75.0%) 和低收入人群教育程度（51.9%高中学历或以下）。除入组率 (54%) 外，可行性和可接受性指标均被超越（77% 的依从性、77% 的保留率、可接受性评分≥8/10）。从干预前到干预后，希望和目标干扰有适度改善（d= 0.51,p< 0.05 表示希望；d=−0.70，p目标干扰< 0.005）。结论强大的可行性、可接受性和患者报告的结果数据表明，Pathways 是一种有前途的干预措施，可以在晚期肺癌治疗期间增加希望并减少与癌症相关的目标干扰。